Updating results

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018

Post-traumatic stress disorder (NG116)

This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.

NICE guideline Published December 2018

Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions (IPG633)

Evidence-based recommendations on percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk PCIs

Interventional procedures guidance Published November 2018

Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (IPG632)

Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults

Interventional procedures guidance Published November 2018

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

Technology appraisal guidance Published November 2018

Padeliporfin for untreated localised prostate cancer (TA546)

Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults

Technology appraisal guidance Published November 2018

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

Technology appraisal guidance Published November 2018

Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis (IPG631)

Evidence-based recommendations on subcutaneous automated low-flow pump implantation for refractory ascites caused by liver cirrhosis in adults

Interventional procedures guidance Published November 2018

Heavy menstrual bleeding: assessment and management (NG88)

This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

NICE guideline Published March 2018 Last updated November 2018

Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (IPG630)

Evidence-based recommendations on selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma in adults

Interventional procedures guidance Published October 2018

Urinary tract infection in under 16s: diagnosis and management (CG54)

This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infections in infants, children and young people. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management.

Clinical guideline Published August 2007 Last updated October 2018

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Myeloma: diagnosis and management (NG35)

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

NICE guideline Published February 2016 Last updated October 2018

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults

Technology appraisal guidance Published October 2018

Lyme disease (NG95)

This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.

NICE guideline Published April 2018 Last updated October 2018

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Highly specialised technologies guidance Published October 2018

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published October 2018

Cabozantinib for untreated advanced renal cell carcinoma (TA542)

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published October 2018

Renal replacement therapy and conservative management (NG107)

This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

NICE guideline Published October 2018

Decision-making and mental capacity (NG108)

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

NICE guideline Published October 2018

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

Technology appraisal guidance Published September 2018

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG629)

Evidence-based recommendations on transurethral water jet ablation for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)

Interventional procedures guidance Published September 2018

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer

Interventional procedures guidance Published September 2018

Chronic heart failure in adults: diagnosis and management (NG106)

This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

NICE guideline Published September 2018

Pancreatitis (NG104)

This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

NICE guideline Published September 2018

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Technology appraisal guidance Published August 2018

Superior rectal artery embolisation for haemorrhoids (IPG627)

Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults

Interventional procedures guidance Published August 2018

Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias (an inserted device to help the heart beat at a normal rate)

Interventional procedures guidance Published August 2018

Sutureless aortic valve replacement for aortic stenosis (IPG624)

Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults

Interventional procedures guidance Published August 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)

Interventional procedures guidance Published August 2018

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of delayed-union and non-union fractures

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (IPG622)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at high risk of non-healing

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (IPG621)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at low risk of non-healing in adults

Interventional procedures guidance Published July 2018

Transaxial interbody lumbosacral fusion for severe chronic low back pain (IPG620)

Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults

Interventional procedures guidance Published July 2018

Superior capsular augmentation for massive rotator cuff tears (IPG619)

Evidence-based recommendations on superior capsular augmentation for massive rotator cuff (shoulder) tears

Interventional procedures guidance Published July 2018

Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Early and locally advanced breast cancer: diagnosis and management (NG101)

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

NICE guideline Published July 2018

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Brain tumours (primary) and brain metastases in adults (NG99)

This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

NICE guideline Published July 2018